George Papadopoulos1, Anna Papadopoulou2, Konstantina Kosma3, Anastasios Papadimitriou1, Vassiliki Papaevangelou1, Christina Kanaka-Gantenbein4, Evangelia Bountouvi1, Sophia Kitsiou-Tzeli5. 1. 3rd Department of Pediatrics, University of Athens, Medical School, University General Hospital "ATTIKON", Chaidari, Greece. 2. 3rd Department of Pediatrics, University of Athens, Medical School, University General Hospital "ATTIKON", Chaidari, Greece. anpapado@med.uoa.gr. 3. Department of Medical Genetics, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 4. Division of Endocrinology, Diabetes and Metabolism, Center for Rare Paediatric Endocrine Diseases, First Department of Paediatrics, Medical School, National and Kapodistrian University of Athens, Agia Sophia Children's Hospital, Athens, Greece. 5. Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Abstract
Noonan syndrome (NS) is an autosomal dominant disorder characterized by clinical and genetic heterogeneity. It belongs to a wider group of pathologies, known as Rasopathies, due to the implication of genes encoding components of the Ras/MAPK signalling pathway. Recording the genetic alterations across populations helps assessing specific features to specific genes which is essential for better disease's recognition, prognosis and monitoring. Herein, we report the clinical and molecular data of a Greek cohort comprising of 86 NS or NS-like patients admitted at a single tertiary Centre in Athens, Greece. The analysis was performed using Sanger and next-generation sequencing, comprising 14 different genes. The mutational rates of the confirmed NS-associated genes in the Greek NS population are as follows: PTPN11 32.5%; RIT1 5.8%; SOS1 4.7%; BRAF 1.2%; CBL 1.2%; KRAS 1.2%; MAP2K1 1.2%; RAF1 1.2%; SHOC2 1.2%, corresponding to 50% of positivity in total NS population. The genotype-phenotype analysis showed statistically significant differences in craniofacial dysmorphisms (p = 0.005) and pulmonary valve stenosis (PS) (p < 0.001) frequencies between patients harbouring a pathogenic variant and patients without pathogenic variant in any of the tested genes. Patients with at least a pathogenic variant had 6.71 times greater odds to develop PS compared to pathogenic variant-negative patients (OR = 6.71, 95%; CI = (2.61, 17.27)). PTPN11 positive patients showed higher frequency of epicanthal folds (p = 0.004), ptosis (p = 0.001) and coarseness (p = 0.001) and lower frequency of neurological findings (p = 0.006), compared to patients carrying pathogenic variants in other genes. CONCLUSION: Craniofacial dysmorphism and PS prevail among pathogenic variant positive compared to pathogenic variant negative NS and NS-like patients while neurological defects are less common in PTPN11-affected NS patients compared to patients harbouring pathogenic variants in other genes. The significant prevalence of the Ras/MAPK pathogenic variants (17.4%), other than PTPN11, in Greek NS patients, highlights the necessity of a wider spectrum of molecular diagnosis. WHAT IS KNOWN: • Noonan syndrome (NS) has been associated with pathogenic variants in molecules-components of the Ras/MAPK pathway. • Clinical and genetic description of NS patients worldwide helps establishing personalized monitoring. WHAT IS NEW: • NS and NS-like mutational rate in Greece reaches 50% with pathogenic variants identified mostly in PTPN11 (32.5%), RIT1 (6%) and SOS1 (4.7%) genes. • The risk for pulmonary stenosis increases 6.71-fold in NS patients with a pathogenic variant compared to patients without genetic alterations.
Noonan syndrome (NS) is an autosomal dominant disorder characterized by clinical and genetic heterogeneity. It belongs to a wider group of pathologies, known as Rasopathies, due to the implication of genes encoding components of the Ras/MAPK signalling pathway. Recording the genetic alterations across populations helps assessing specific features to specific genes which is essential for better disease's recognition, prognosis and monitoring. Herein, we report the clinical and molecular data of a Greek cohort comprising of 86 NS or NS-like patients admitted at a single tertiary Centre in Athens, Greece. The analysis was performed using Sanger and next-generation sequencing, comprising 14 different genes. The mutational rates of the confirmed NS-associated genes in the Greek NS population are as follows: PTPN11 32.5%; RIT1 5.8%; SOS1 4.7%; BRAF 1.2%; CBL 1.2%; KRAS 1.2%; MAP2K1 1.2%; RAF1 1.2%; SHOC2 1.2%, corresponding to 50% of positivity in total NS population. The genotype-phenotype analysis showed statistically significant differences in craniofacial dysmorphisms (p = 0.005) and pulmonary valve stenosis (PS) (p < 0.001) frequencies between patients harbouring a pathogenic variant and patients without pathogenic variant in any of the tested genes. Patients with at least a pathogenic variant had 6.71 times greater odds to develop PS compared to pathogenic variant-negative patients (OR = 6.71, 95%; CI = (2.61, 17.27)). PTPN11 positive patients showed higher frequency of epicanthal folds (p = 0.004), ptosis (p = 0.001) and coarseness (p = 0.001) and lower frequency of neurological findings (p = 0.006), compared to patients carrying pathogenic variants in other genes. CONCLUSION: Craniofacial dysmorphism and PS prevail among pathogenic variant positive compared to pathogenic variant negative NS and NS-like patients while neurological defects are less common in PTPN11-affected NS patients compared to patients harbouring pathogenic variants in other genes. The significant prevalence of the Ras/MAPK pathogenic variants (17.4%), other than PTPN11, in Greek NS patients, highlights the necessity of a wider spectrum of molecular diagnosis. WHAT IS KNOWN: • Noonan syndrome (NS) has been associated with pathogenic variants in molecules-components of the Ras/MAPK pathway. • Clinical and genetic description of NS patients worldwide helps establishing personalized monitoring. WHAT IS NEW: • NS and NS-like mutational rate in Greece reaches 50% with pathogenic variants identified mostly in PTPN11 (32.5%), RIT1 (6%) and SOS1 (4.7%) genes. • The risk for pulmonary stenosis increases 6.71-fold in NS patients with a pathogenic variant compared to patients without genetic alterations.
Authors: Guilherme Lopes Yamamoto; Meire Aguena; Monika Gos; Christina Hung; Jacek Pilch; Somayyeh Fahiminiya; Anna Abramowicz; Ingrid Cristian; Michelle Buscarilli; Michel Satya Naslavsky; Alexsandra C Malaquias; Mayana Zatz; Olaf Bodamer; Jacek Majewski; Alexander A L Jorge; Alexandre C Pereira; Chong Ae Kim; Maria Rita Passos-Bueno; Débora Romeo Bertola Journal: J Med Genet Date: 2015-03-20 Impact factor: 6.318
Authors: Andrew R Grant; Brandon J Cushman; Hélène Cavé; Mitchell W Dillon; Bruce D Gelb; Karen W Gripp; Jennifer A Lee; Heather Mason-Suares; Katherine A Rauen; Marco Tartaglia; Lisa M Vincent; Martin Zenker Journal: Hum Mutat Date: 2018-11 Impact factor: 4.878
Authors: M Tartaglia; E L Mehler; R Goldberg; G Zampino; H G Brunner; H Kremer; I van der Burgt; A H Crosby; A Ion; S Jeffery; K Kalidas; M A Patton; R S Kucherlapati; B D Gelb Journal: Nat Genet Date: 2001-12 Impact factor: 38.330
Authors: Andrea M Gross; Megan Frone; Karen W Gripp; Bruce D Gelb; Lisa Schoyer; Lisa Schill; Beth Stronach; Leslie G Biesecker; Dominic Esposito; Edjay Ralph Hernandez; Eric Legius; Mignon L Loh; Staci Martin; Deborah K Morrison; Katherine A Rauen; Pamela L Wolters; Dina Zand; Frank McCormick; Sharon A Savage; Douglas R Stewart; Brigitte C Widemann; Marielle E Yohe Journal: Am J Med Genet A Date: 2020-01-08 Impact factor: 2.578
Authors: Lisenka E L M Vissers; Monica Bonetti; Jeroen Paardekooper Overman; Willy M Nillesen; Suzanna G M Frints; Joep de Ligt; Giuseppe Zampino; Ana Justino; José C Machado; Marga Schepens; Han G Brunner; Joris A Veltman; Hans Scheffer; Piet Gros; José L Costa; Marco Tartaglia; Ineke van der Burgt; Helger G Yntema; Jeroen den Hertog Journal: Eur J Hum Genet Date: 2014-06-18 Impact factor: 4.246